aiqbench analysis
This research applies machine learning models to predict whether a drug compound will yield a usable potency estimate in follow-up assays, distinguishing "quantifiability" from mere biological activity. By leveraging low-cost screening features rather than molecular structure, the framework enables more efficient allocation of expensive dose-response profiling resources across diverse chemical scaffolds and assay mechanisms.
Predicting Quantifiability from Primary Screens to Prioritize Dose-Response Profiling
arXiv:2608.26538v1 Announce Type: new Abstract: High-throughput drug screening relies on low-cost primary assays to prioritize compounds for more expensive dose-response profiling, where potency is ultimately quantified. Current screening strategies largely focus on identifying compounds that will confirm biological activity on follow-up, implicitly assuming that confirmed activity will also yield a usable potency estimate. However, confirmed biological activity in screening does not necessarily translate into a quantifiable potency, because active compounds can still fail to produce a reportable dose-response estimate. We therefore present a framework for modeling quantifiability, whether follow-up testing will yield a usable potency estimate, as a distinct triage objective from biological activity. Quantifiability was strongly predictable from the preceding low-cost screen, with most predictive information arising from the observed screening features rather than molecular structure. Response-based predictors remained robust on previously unseen chemical scaffolds and generalized across held-out assay-mechanism families, while the probability of successful quantification varied strongly with response amplitude and assay context. These findings establish experimental measurability, distinct from biological activity, as a predictable property of screening outcomes and show that quantifiability-aware triage can improve the allocation of costly dose-response profiling capacity.
Abstract:High-throughput drug screening relies on low-cost primary assays to prioritize compounds for more expensive dose-response profiling, where potency is ultimately quantified. Current screening strategies largely focus on identifying compounds that will confirm biological activity on follow-up, implicitly assuming that confirmed activity will also yield a usable potency estimate. However, confirmed biological activity in screening does not necessarily translate into a quantifiable potency, because active compounds can still fail to produce a reportable dose-response estimate. We therefore present a framework for modeling quantifiability, whether follow-up testing will yield a usable potency estimate, as a distinct triage objective from biological activity. Quantifiability was strongly predictable from the preceding low-cost screen, with most predictive information arising from the observed screening features rather than molecular structure. Response-based predictors remained robust on previously unseen chemical scaffolds and generalized across held-out assay-mechanism families, while the probability of successful quantification varied strongly with response amplitude and assay context. These findings establish experimental measurability, distinct from biological activity, as a predictable property of screening outcomes and show that quantifiability-aware triage can improve the allocation of costly dose-response profiling capacity.
Machine Learning (cs.LG); Biomolecules (q-bio.BM)
arXiv:2608.26538 [cs.LG]
(or arXiv:2608.26538v1 [cs.LG] for this version)
https://doi.org/10.48550/arXiv.2608.26538 Focus to learn more arXiv-issued DOI via DataCite (pending registration)
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Full text under the publisher's open licence · 277 words
Related coverage

AI in healthcare: applications and best practices
Databricks · Jul 24, 2026
Quantifying Rodda and Graham Gait Classification from 3D Markerless Kinematics derived from a Single-view Video in a Heterogeneous Pediatric Clinical Cohort
arXiv · Jun 9, 2026
CASCADE Conformal Prediction: Uncertainty-Adaptive Prediction Intervals for Two-Stage Clinical Decision Support
arXiv · Jun 5, 2026
CASCADE Conformal Prediction: Uncertainty-Adaptive Prediction Intervals for Two-Stage Clinical Decision Support
arXiv · Oct 2, 2026